Ramiro Sanchez

CIK: 0001830326

Transaction Breakdown

Open Market Buys (P)1 (12.5%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (87.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

RAPP

Rapport Therapeutics, Inc.

Director

ANRO

Alto Neuroscience, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

RAPP
Rapport Therapeutics, Inc.
Oct 23, 2026
Purchase(P)
Direct
3.6K shares at avg. $27.35$98K
RAPP
Rapport Therapeutics, Inc.
Jun 10, 2026
Award(A)
Stock Option (Right to Buy)
Direct
15.2K shares-
ANRO
Alto Neuroscience, Inc.
May 12, 2026
Award(A)
Stock Option (right to buy)
Direct
11K shares-
ANRO
Alto Neuroscience, Inc.
Jan 2, 2026
Award(A)
Stock Option (right to buy)
Direct
3.8K shares at avg. $11.82-
ANRO
Alto Neuroscience, Inc.
Aug 12, 2025
Award(A)
Stock Option (right to buy)
Direct
30.6K shares-
ANRO
Alto Neuroscience, Inc.
Aug 12, 2025
Award(A)
Stock Option (right to buy)
Direct
3.9K shares at avg. $2.21-
RAPP
Rapport Therapeutics, Inc.
Jun 17, 2025
Award(A)
Stock Option (Right to Buy)
Direct
10.9K shares-
RAPP
Rapport Therapeutics, Inc.
Nov 7, 2024
Award(A)
Stock Option (Right to Buy)
Direct
29.8K shares-

		Type	Shares	Price		Ownership
Oct 23, 2026	RAPP Rapport Therapeutics, Inc.	Purchase(P)	3,600	$27.35	$98,478	Direct
Jun 10, 2026	RAPP Rapport Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	15,200	-	-	Direct
May 12, 2026	ANRO Alto Neuroscience, Inc.	Award(A) Stock Option (right to buy)	10,958	-	-	Direct
Jan 2, 2026	ANRO Alto Neuroscience, Inc.	Award(A) Stock Option (right to buy)	3,806	$11.82	-	Direct
Aug 12, 2025	ANRO Alto Neuroscience, Inc.	Award(A) Stock Option (right to buy)	30,574	-	-	Direct
Aug 12, 2025	ANRO Alto Neuroscience, Inc.	Award(A) Stock Option (right to buy)	3,928	$2.21	-	Direct
Jun 17, 2025	RAPP Rapport Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	10,925	-	-	Direct
Nov 7, 2024	RAPP Rapport Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	29,756	-	-	Direct

1-8 of 8 transactions

About Sanchez Ramiro

Sanchez Ramiro (SEC CIK 0001830326) files insider reports with the SEC as Director of Rapport Therapeutics, Inc. (RAPP) and Director of Alto Neuroscience, Inc. (ANRO).

Signal8 holds 9 ownership filings by Sanchez Ramiro (2 Form 3, 7 Form 4), filed between Nov 7, 2024 and Oct 23, 2026. Those filings report 8 transactions, from Nov 7, 2024 to Oct 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Sanchez Ramiro's filings is in BOSTON, MA.

Recent filings by Sanchez Ramiro

Oct 23, 2026: Open-market purchase of RAPP shares (Form 4, code P).
Jun 10, 2026: Grant or award of RAPP derivative securities (Form 4, code A).
May 12, 2026: Grant or award of ANRO derivative securities (Form 4, code A).
Jan 2, 2026: Grant or award of ANRO derivative securities (Form 4, code A).
Aug 12, 2025: Grants or awards of ANRO derivative securities (2 lines, Form 4, code A).

Other insiders filing for Rapport Therapeutics, Inc. (RAPP)

HEALY JAMES, Director
Ceesay Abraham, Chief Executive Officer
Silva Paul M, Director
Young Wendy B., Director
PAUL STEVEN M, Director
MARAGANORE JOHN, Director

How to read Form 4 transaction codes